Rating Change
BTIG analysts initiated coverage on Serina Therapeutics, Inc. (NYSE:SER) with a Buy rating on July 01, 2026.
new coverageNYSE:SER
BTIG Initiates Coverage on Serina Therapeutics, Inc. (SER) with Buy
Rating Change BTIG analysts initiated coverage on Serina Therapeutics, Inc. (NYSE:SER) with a Buy rating on July 01, 2026. Market Context Serina Therapeutics, Inc.
Market Context
Serina Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $1.92 with a market capitalization of $33.5M.
Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Serina Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Serina Therapeutics, Inc.
Among the 4 most recent ratings: 4 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 01, 2026 | BTIG | Buy | N/A |
| Aug 28, 2025 | HC Wainwright & Co. | Buy | N/A |
| Jul 14, 2025 | HC Wainwright & Co. | Buy | N/A |
| Mar 11, 2025 | Jones Trading | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View SER Stock Page
Frequently Asked Questions
What does a Buy rating mean for SER?
A Buy rating from BTIG reflects the analyst's outlook on Serina Therapeutics, Inc. (NYSE:SER). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SER forecast page.